UroGen reports Q2 loss of $49.9M; launches ZUSDURI after June FDA approval

UroGen Pharma Ltd.

ZUSDURI (mitomycin) FDA-approved June 12 for recurrent LG-IR-NMIBC; now commercially available.
JELMYTO Q2 net revenue $24.2M (+11% vs Q2 2024); FY guidance $94-98M unchanged.
Net loss $49.9M ($1.05/share) vs $33.4M ($0.82) in Q2 2024; operating loss $41.4M.
Cash and marketable securities $161.6M at June 30, 2025.
Enrollment complete in Phase 3 UTOPIA trial for next-gen mitomycin UGN-103.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.